Aaron Miller

Dr. Aaron Miller


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LWLamont J. Wilkins
Lamont J. Wilkins
MMManoj Monga
Manoj Monga
AMAaron Miller
Aaron Miller
The prevalence of many chronic diseases has increased over the last decades. It has been postulated that dysbiosis driven by environmental factors such as antibiotic use is shifting the microbiome in ways that increase inflammation and the onset of chronic disease. Dysbiosis can be defined through the loss or gain of bacteria that either promote health or disease, respectively. Here we use multiple independent datasets to determine the nature of dysbiosis for a cluster of chronic diseases that includes urinary stone disease (USD), obesity, diabetes, cardiovascular disease, and kidney disease, which often exist as co-morbidities. For all disease states, individuals exhibited a statistically significant association with antibiotics in the last year compared to healthy counterparts. There was also a statistically significant association between antibiotic use and gut microbiota composition. Furthermore, each disease state was associated with a loss of microbial diversity in the gut. Three genera,Bacteroides, Prevotella, andRuminococcus, were the most common dysbiotic taxa in terms of being enriched or depleted in disease populations and was driven in part by the diversity of operational taxonomic units (OTUs) within these genera. Results of the cross-sectional analysis suggest that antibiotic-driven loss of microbial diversity may increase the risk for chronic disease. However, longitudinal studies are needed to confirm the causative effect of diversity loss for chronic disease risk.

1 April 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AZAnna Zampini
Anna Zampini
ANAndrew H. Nguyen
Andrew H. Nguyen
EREmily Rose
Emily Rose
MMManoj Monga
Manoj Monga
AMAaron Miller
Aaron Miller
The prevalence of urinary stone disease (USD) is rapidly rising. However, the factors driving this increase are unknown. Recent microbiome studies suggest that dysbiosis may in part contribute to the increasing prevalence. The objective of the current study was to determine the nature and location of dysbiosis associated with USD. We conducted microbiome analysis from the gastrointestinal and urinary tracts, along with a metabolomic analysis of the urinary metabolome, from subjects with an active episode of USD or no history of the disease. Higher rates of antibiotic use among USD patients along with integrated microbiome and metabolomic results support the hypothesis that USD is associated with an antibiotic-driven shift in the microbiome from one that protects against USD to one that promotes the disease. Specifically, our study implicates urinary tract Lactobacillus and Enterobacteriaceae in protective and pathogenic roles for USD, respectively, which conventional, culture-based methods of bacterial analysis from urine and kidney stones would not necessarily detect. Results suggest that antibiotics produce a long-term shift in the microbiome that may increase the risk for USD, with the urinary tract microbiome holding more relevance for USD than the gut microbiome.

1 July 2019 in Kidney International
Verified
Journal Article
Closed access
AMAaron Miller
Aaron Miller
DCDavid Choy
David Choy
KPKristina L. Penniston
Kristina L. Penniston
Dirk LangeDirk Lange
Dirk Lange

20 September 2022 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
AMAaron Miller
Aaron Miller
KPKristina L. Penniston
Kristina L. Penniston
KFKate Fitzpatrick
Kate Fitzpatrick
JAJosé Agudelo
José Agudelo
GTGregory Tasian
Gregory Tasian
Dirk LangeDirk Lange
Dirk Lange

28 July 2025 in Nature Reviews Nephrology
Verified
Journal Article
Open access
PDF file
PBPatricia Bloom
Patricia Bloom
WGWendy S. Garrett
Wendy S. Garrett
KPKristina L. Penniston
Kristina L. Penniston
MWMari-Karoliina H. Winkler
Mari-Karoliina H. Winkler
SHStanley L. Hazen
Stanley L. Hazen
JPJennifer L. Pluznick
Jennifer L. Pluznick
More than 850 million individuals worldwide, accounting for 10–15% of the adult population, are estimated to have chronic kidney disease. Each of these individuals is host to tens of trillions of microorganisms that are collectively referred to as microbiota — a dynamic ecosystem that both influences host health and is itself influenced by changes in the host. Available evidence supports the existence of functional connections between resident microorganisms and kidney health that are altered in the context of specific kidney diseases, including acute kidney injury, chronic kidney disease and renal stone disease. Moreover, promising data from preclinical studies suggest that targeting of gut microbial pathways may provide new therapeutic opportunities for the treatment of kidney disease. This Roadmap describes current understanding of the mechanisms by which microorganisms regulate host organ function, the effects of kidney disease on the gut microbiome, and how these insights may contribute to the development of microbe-targeted therapeutics. We highlight key knowledge gaps that remain to be addressed and strategies for addressing these, outlining both the promise and the potential pitfalls of leveraging our understanding of the gut microbiota to better understand and treat kidney disease.

31 October 2017 in mSystems
Verified
Journal Article
Open access
PDF file
AMAaron Miller
Aaron Miller
CDColin Dale
Colin Dale
MDM. Denise Dearing
M. Denise Dearing
Oxalate is a central component in 80% of kidney stones. While mammals do not possess the enzymes to degrade oxalate, many gastrointestinal bacteria are efficient oxalate degraders. We examined the role of cohesive microbial networks for oxalate metabolism, using Sprague-Dawley rats as a model host. While the transplantation of oxalate-degrading bacteria alone to the Sprague-Dawley hosts did increase oxalate metabolism, fecal transplants from a wild mammalian herbivore, Neotoma albigula , had a significantly greater effect. Furthermore, the boost for oxalate metabolism persisted only in animals that received fecal transplants. Animals receiving fecal transplants had a more diverse and cohesive network of bacteria associated with the Oxalobacteraceae , a family known to consist of specialist oxalate-degrading bacteria, than did animals that received oxalate-degrading bacteria alone. Our results indicate that fecal transplants are more effective at transferring specific functions than are microbial specialists alone, which has broad implications for the development of bacteriotherapies.